
|Articles|October 28, 2021
Pharmacy Clinical Pearl of the Day: Colon Cancer
Author(s)Saro Arakelians, PharmD
Chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Advertisement
Clinical Pearl of the Day: Colon Cancer
Colon cancer is a type of cancer that begins in the large intestine (colon).
Insight:
- Colon cancer typically affects older adults, though it can happen at any age.
- Symptoms may include change in bowel habits, diarrhea, constipation, rectal bleeding, persistent abdominal discomfort, weakness or fatigue, and unexplained weight loss.
- Risk factors include older age, African American race, history of colorectal cancer, inflammatory intestinal conditions, obesity, diabetes, smoking, alcohol use, and family history.
- Treatment includes polypectomy, mucosal resection, partial colectomy, lymph nodes removal, chemotherapy, radiation therapy, targeted drug therapy, immunotherapy, and palliative care.
- Some drugs used as chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
FDA Approves Gepotidacin for Urogenital Gonorrhea in Adult and Pediatric Patients
3
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
4
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
5





















































































































































































































